Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02558413 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers
A Phase 1 study, sponsored by Biota Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02558413: Completed Phase 1 study, sponsored by Biota Pharmaceuticals.
NCT02558413 is a Phase 1 study that has completed, run by Biota Pharmaceuticals. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02558413, a Phase 1 study, has completed, sponsored by Biota Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This is a placebo-controlled, double-blind, randomized, single dose escalation Phase 1 clinical trial to determine the safety and tolerability of BTA-C585 administered orally to healthy subjects.
Interventions
- DRUG BTA-C585 oral capsules
- DRUG BTA-C585 matching placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-08 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02558413
The ClinicalTrials.gov registry entry for NCT02558413 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biota Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BTA-C585 oral capsules is the first listed.
NCT02558413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02558413 about?
NCT02558413 is a clinical study titled "Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers". This is a placebo-controlled, double-blind, randomized, single dose escalation Phase 1 clinical trial to determine the safety and tolerability of BTA-C585 administered orally to healthy subjects.
What is the current status of trial NCT02558413?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-08. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02558413?
The interventions under investigation include: BTA-C585 oral capsules (DRUG), BTA-C585 matching placebo (DRUG).
Who is sponsoring clinical trial NCT02558413?
This trial is sponsored by Biota Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.